news
Mitochondrial DNA could predict risk for sudden cardiac death
New studies add to evidence of link between mitochondrial DNA copy number and risk for cardiovascular disease...
List view / Grid view
Cardiovascular disease
news
New WHO Collaborating Centre for Physical Activity and Health
The University of Zurich is launching a new WHO Collaborating Centre for Physical Activity and Health. The Physical Activity and Health Unit and other groups of the Epidemiology, Biostatistics and Prevention Institute will support the Physical Activity Strategy for the World Health Organization (WHO) European Region.
news
Diabetes drug prevents cardiovascular disease in obese mouse study
A study by researchers at the University of Missouri School of Medicine found that the diabetes medication linagliptin can protect against stiffening of the left ventricle of the heart in overweight female mice. The finding may have implications for management of cardiovascular disease in humans.
news
IDF calls for internationally standardised monitoring of cardiovascular disease in diabetics
29 September 2016 | By Niamh Louise Marriott, Digital Content Producer
It is difficult to estimate the global burden of cardiovascular disease in people with diabetes, due to lack of data and standardisation...
article
Vigilin: Could this drug target prevent a heart attack?
27 September 2016 | By ETH Zürich
Scientists identified a protein in liver cells, known as vigilin, which regulates the release of fats from the liver into the bloodstream. Find out more...
news
A*STAR and MSD team up to advance peptide therapeutics
19 July 2016 | By Niamh Louise Marriott
A*STAR and MSD have formed a two year collaboration aimed at improving cellular delivery of macrocyclic peptides...
news
Winners of innovative cardiovascular research grant programme announced
11 February 2016 | By Victoria White
The European Society of Cardiology awarded the grants to research projects that will address areas of unmet medical need in thromboembolic disease...
news
Phase 3a liraglutide 3 mg trial demonstrated significant weight loss and improved cardiovascular risk factors in adults with obesity and type 2 diabetes compared with placebo
23 June 2014 | By Novo Nordisk
New data from the phase 3a SCALE™ Diabetes trial were presented at the International Congress of Endocrinology and the Endocrine Society’s meeting, investigating the effect of liraglutide 3 mg in adults...
news
Sanford-Burnham and Daiichi Sankyo form alliance to study novel drug targets in cardiovascular-metabolic diseases
22 May 2014 | By Daiichi Sankyo
Sanford-Burnham Medical Research Institute and Daiichi Sankyo Co., Ltd. announced they have entered into a three-year comprehensive alliance to develop first-in-class therapeutics for the treatment of cardiovascular-metabolic diseases...